Attention IASLC Voting Members!!

Check your email for "Your Vote Matters: Cast Your Ballot on IASLC Bylaws Today" OR cast your ballot now

LAURA Trial Part 1

Episode
265
Soundcloud
Share

Lung Cancer Considered host Dr. Narjust Florez and Dr. Suresh Ramalingam discuss the recent FDA approval of osimertinib after chemo-radiation in EGFR-positive NSCLC. The approval was based, in part, on the results of the LAURA trial, which was presented at the 2024 ASCO Annual Meeting. Tune in and hear about this important trial from the lead author.

Guest
Narjust Florez
Narjust Florez

MD

Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
 Suresh Ramalingam
Suresh Ramalingam

MD, FACP, FASCO

Professor, Department of Hematology and Medical Oncology
Emory University Winship Cancer Institute

Other Podcast

Phase III CheckMate 77T Study
Episode
269
FDA Approval: TTFields for NSCLC
Episode
268
ESMO Asia 2024 Highlights
Episode
267